Kenny Walker-Durrant

Venture Capital Financings

• advised Myricx Bio, a biotech company developing a first in class of ADC platform based on NMT inhibition to treat cancer, on its £90 million Series A financing, co-led by Novo Holdings and Abingworth
• advised a syndicate of investors led by Forbion on the $170 million Series B investment into Beacon Therapeutics, an ophthalmic gene therapy company focused on restoring the vision in patients with rare and prevalent retinal diseases 
• advised a syndicate of investors led by EQT Life Sciences and Sectoral Asset Management on the $42 million Series D investment into Phagenesis, a medical device company specialising in the treatment of swallowing disorders
• advised Forbion Growth Opportunities Fund and Sofinnova Investments as lead investors on the $148 million Series C investment into Gyroscope Therapeutics, a clinical-stage gene therapy company developing gene therapy targeting vision loss
• advised Jeito Capital as lead investor on the $92 million Series C financing of Pulmocide, a biopharmaceutical company developing inhaled treatments for respiratory diseases
• advised Andera Partners and LSP on the £65 million Series B investment into Artios Pharma, a biotech company pioneering DDR-based cancer therapies
• advised Achilles Therapeutics, a biopharma company developing personalised T cell therapies for solid tumours, on its £100 million Series B financing led by RA Capital and its £52.7 million Series C financing led by OrbiMed, Boxer Capital of Tavistock Group, and other prominent US-based investors
• advised Gilde Healthcare, Kaiser Permanente Ventures and Morningside Ventures on the $75 million Series C financing of Big Health, a digital mental health care provider 
• advised Quanta Dialysis Technologies, a medtech company developing a personal haemodialysis system (SC+), on its $48 million Series C funding financing led by a Swiss private family office with participation from btov Partners, Wellington Partners and Seroba Life Sciences
• advised Bicycle Therapeutics, a biopharma company developing “Bicycles”, on its £40 million Series B financing, led by Vertex* and on its $27.9 million Series B2 financing, led by Tybourne

M&A

• advised Alys Pharmaceuticals on the acquisition of six biotech companies all with dermatology programs backed with $100 million in financing  
• advised Centessa Pharmaceuticals on the acquisition of ten biotech companies and its concurrent $250 million Series A financing 
• advised Ducentis Biotherapeutics, a biotech company developing therapies for inflammation and autoimmune diseases, on its acquisition by Nasdaq listed Arcutis Biotherapeutics, Inc. for up to $400 million
• advised DJS Antibodies, a biotech company focused on GPCR targeting antibody medicines, on its acquisition by AbbVie
• advised ReViral Limited, a clinical-stage biopharma company developing antiviral therapeutics, with an initial focus on treating respiratory syncytial virus, on its acquisition by Pfizer for total consideration of up to $525 million
• advised Enterprise Therapeutics on the demerger and sale of its TMEM16A potentiator portfolio to Roche for upfront consideration of £75 million and potential milestone payments (having also advised the lead investors on its series B investment)
• advised Prexton Therapeutics, a biotech company developing foliglurax for the symptomatic treatment of Parkinson’s disease and dyskinesia (including Levodopa Induced Dyskinesia), on its acquisition by H. Lundbeck A/S for up to €905 million*
• advised Stat-Dx, a diagnostics company creating fully integrated molecular diagnostics, on its acquisition by QIAGEN for up to $191 million*
• advised Ziarco Group, a biotech company developing  treatments in dermatology, on its acquisition by Novartis*
• advised XO1, a biotech company developing Ichorcumab, a novel anticoagulant to treat Thrombosis, on its acquisition by Janssen Pharmaceuticals*

IPOs

• advised Centessa Pharmaceuticals on its $379.5 million IPO on Nasdaq
• advised Achilles Therapeutics on its $175.5 million IPO on Nasdaq
• advised Bicycle Therapeutics on its $60 million IPO on Nasdaq

*Denotes experience prior to joining Goodwin.

Venture Capital Financings

• advised Matillion, a cloud-native data integration and transformation platform, on its $150 million Series E financing led by General Atlantic 
• advised Y Combinator as lead investor on the £113 million Series F investment and its participation in the subsequent £60m Series G investment into Monzo Bank, a UK based digital bank
• advised DST Global and General Catalyst on the $150 million Series C investment into Zego, a motor insurtech company
• advised Cognitive Credit, a software company providing credit investors with specialist data and analytics, on its $10 million Series B round led by ETFS Capital 
• advised OMERS Ventures Europe on the €18.5 million Series B investment into FirstVet, a telemedicine provider for pets
• advised EQT on the £12 million Series A investment into Peanut App, a female social network platform
• advised Grip, a market engagement platform, on its $13 million Series A financing led by Kennet Partners
• advised Index Ventures on the $11.5 million Series A investment into Birdie, a caretech platform reinventing home care
• advised Lakestar, a European venture capital firm that invests from seed to growth in the tech sector, on multiple investments into UK tech companies
• advised Cherry Ventures, a European early-stage venture firm in the tech sector, on multiple early-stage investments into UK tech companies

M&A

• advised Sportpursuit, an online sports product private sales platform, on its majority sale to BD-Capital
• advised Fixflo (Tactile), a provider of property repairs and maintenance software, on its acquisition by Aareon AG
• advised Symprove, a probiotics manufacturer, on its majority sale to BD-Capital
• advised Profile Pensions, a digital pension adviser, on its acquisition by Moneyfarm
• advised Capital Z Partners on its acquisition of Prestige Insurance (the largest privately owned insurance broker and managing general agent in Northern Ireland)
• advised Captify, a search intelligence platform, on its acquisition by SFW Capital Partners
• advised Weezy, an online on-demand grocery delivery platform, on its acquisition by Getir
• advised Springer Nature on its acquisition of the British Journal of Cancer publishing platform from Cancer Research UK

*Denotes experience prior to joining Goodwin.